Does INFLIXIMAB, RECOMBINANT Cause Neoplasm malignant? 5 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Neoplasm malignant have been filed in association with INFLIXIMAB, RECOMBINANT. This represents 2.0% of all adverse event reports for INFLIXIMAB, RECOMBINANT.
5
Reports of Neoplasm malignant with INFLIXIMAB, RECOMBINANT
2.0%
of all INFLIXIMAB, RECOMBINANT reports
1
Deaths
1
Hospitalizations
How Dangerous Is Neoplasm malignant From INFLIXIMAB, RECOMBINANT?
Of the 5 reports, 1 (20.0%) resulted in death, 1 (20.0%) required hospitalization.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB, RECOMBINANT. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does INFLIXIMAB, RECOMBINANT Cause?
Pneumocystis jirovecii pneumonia (29)
Off label use (21)
Infusion related reaction (18)
Histoplasmosis disseminated (16)
Tuberculosis (15)
Lupus-like syndrome (13)
Pulmonary tuberculosis (12)
Drug ineffective (11)
Pneumonia (11)
Crohn's disease (9)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which INFLIXIMAB, RECOMBINANT Alternatives Have Lower Neoplasm malignant Risk?
INFLIXIMAB, RECOMBINANT vs INFLUENZA A VIRUS A/CALIFORNIA/7/2009 LIVE ANTIGEN\INFLUENZA A VIRUS A/TEXAS/50/2012 LIVE ANTIGEN\INFLUENZA B VIRUS B/BRISBANE/60/2008 LIVE ANTIGEN\INFLUENZA B VIRUS B/MASSACHUSETTS/2/2012 LIVE ANTIGEN
INFLIXIMAB, RECOMBINANT vs INFLUENZA VIRUS VACCINE
INFLIXIMAB, RECOMBINANT vs INFLUENZA VIRUS VACCINE QUADRIVALENT TYPE A+B
INFLIXIMAB, RECOMBINANT vs INGENOL MEBUTATE
INFLIXIMAB, RECOMBINANT vs INLYTA